Overexpression of cyclooxygenase-2 in nasopharyngeal carcinoma and association with epidermal growth factor receptor expression

Ross Soo, Thomas Putti, Qian Tao, Boon Cher Goh, Kang Hoe Lee, Loh Kwok-Seng, Luke Tan, Wen Son Hsieh

Research output: Contribution to journalArticle

Abstract

Objectives: To examine the association between cyclooxygenase-2 (COX-2) expression with epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), inducible nitric oxide synthase (iNOS), and latent membrane protein 1 (LMP-1) expression and with COX-2 promoter methylation status in primary nasopharyngeal cancer (NPC) tumors and to determine COX-2 promoter methylation status in NPC cell lines. Design: Retrospective study. Setting: Patients with NPC were referred to the Department of Otolaryngology-Head and Neck Surgery for treatment. Patients: Formalin-fixed, paraffin-embedded NPC specimens from 42 patients were obtained. Interventions: Immunohistochemical expression of COX-2, EGFR, VEGF, iNOS, and LMP-1 was performed in 42 NPC samples. COX-2 promoter methylation status was studied in 20 separate specimens and in 4 NPC cell lines. Main Outcome Measures: (1) COX-2, EGFR, VEGF, iNOS, and LMP-1 expression; and (2) COX-2 promoter methylation status. Results: COX-2 was overexpressed in 79% of NPC specimens and was associated with EGFR status (P=.03) but not with LMP-1 or iNOS. In primary NPC tissue, methylation of the COX-2 promoter was seen in 4 of 7 COX-2-negative and 1 of 13 COX-2-positive immunohistochemical cases. COX-2 promoter methylation was found in the CNE-1 cell line. Conclusions: Nasopharyngeal cancer may be a useful target for selective COX-2 inhibition. The absence of promoter methylation may be a necessary component of COX-2 overexpression, and promoter methylation may be one of the mechanisms that regulate COX-2 expression.

Original languageEnglish (US)
Pages (from-to)147-152
Number of pages6
JournalArchives of Otolaryngology--Head and Neck Surgery
Volume131
Issue number2
DOIs
StatePublished - Feb 2005

Fingerprint

Cyclooxygenase 2
Epidermal Growth Factor Receptor
Nasopharyngeal Neoplasms
Methylation
Nitric Oxide Synthase Type II
Membrane Proteins
Vascular Endothelial Growth Factor A
Nasopharyngeal carcinoma
Cell Line
Cyclooxygenase 1
Otolaryngology
Paraffin
Formaldehyde
Neck

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Overexpression of cyclooxygenase-2 in nasopharyngeal carcinoma and association with epidermal growth factor receptor expression. / Soo, Ross; Putti, Thomas; Tao, Qian; Goh, Boon Cher; Lee, Kang Hoe; Kwok-Seng, Loh; Tan, Luke; Hsieh, Wen Son.

In: Archives of Otolaryngology--Head and Neck Surgery, Vol. 131, No. 2, 02.2005, p. 147-152.

Research output: Contribution to journalArticle

Soo, Ross ; Putti, Thomas ; Tao, Qian ; Goh, Boon Cher ; Lee, Kang Hoe ; Kwok-Seng, Loh ; Tan, Luke ; Hsieh, Wen Son. / Overexpression of cyclooxygenase-2 in nasopharyngeal carcinoma and association with epidermal growth factor receptor expression. In: Archives of Otolaryngology--Head and Neck Surgery. 2005 ; Vol. 131, No. 2. pp. 147-152.
@article{42f26654504d4ec080893be13d8cba61,
title = "Overexpression of cyclooxygenase-2 in nasopharyngeal carcinoma and association with epidermal growth factor receptor expression",
abstract = "Objectives: To examine the association between cyclooxygenase-2 (COX-2) expression with epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), inducible nitric oxide synthase (iNOS), and latent membrane protein 1 (LMP-1) expression and with COX-2 promoter methylation status in primary nasopharyngeal cancer (NPC) tumors and to determine COX-2 promoter methylation status in NPC cell lines. Design: Retrospective study. Setting: Patients with NPC were referred to the Department of Otolaryngology-Head and Neck Surgery for treatment. Patients: Formalin-fixed, paraffin-embedded NPC specimens from 42 patients were obtained. Interventions: Immunohistochemical expression of COX-2, EGFR, VEGF, iNOS, and LMP-1 was performed in 42 NPC samples. COX-2 promoter methylation status was studied in 20 separate specimens and in 4 NPC cell lines. Main Outcome Measures: (1) COX-2, EGFR, VEGF, iNOS, and LMP-1 expression; and (2) COX-2 promoter methylation status. Results: COX-2 was overexpressed in 79{\%} of NPC specimens and was associated with EGFR status (P=.03) but not with LMP-1 or iNOS. In primary NPC tissue, methylation of the COX-2 promoter was seen in 4 of 7 COX-2-negative and 1 of 13 COX-2-positive immunohistochemical cases. COX-2 promoter methylation was found in the CNE-1 cell line. Conclusions: Nasopharyngeal cancer may be a useful target for selective COX-2 inhibition. The absence of promoter methylation may be a necessary component of COX-2 overexpression, and promoter methylation may be one of the mechanisms that regulate COX-2 expression.",
author = "Ross Soo and Thomas Putti and Qian Tao and Goh, {Boon Cher} and Lee, {Kang Hoe} and Loh Kwok-Seng and Luke Tan and Hsieh, {Wen Son}",
year = "2005",
month = "2",
doi = "10.1001/archotol.131.2.147",
language = "English (US)",
volume = "131",
pages = "147--152",
journal = "Archives of Otolaryngology",
issn = "2168-6181",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - Overexpression of cyclooxygenase-2 in nasopharyngeal carcinoma and association with epidermal growth factor receptor expression

AU - Soo, Ross

AU - Putti, Thomas

AU - Tao, Qian

AU - Goh, Boon Cher

AU - Lee, Kang Hoe

AU - Kwok-Seng, Loh

AU - Tan, Luke

AU - Hsieh, Wen Son

PY - 2005/2

Y1 - 2005/2

N2 - Objectives: To examine the association between cyclooxygenase-2 (COX-2) expression with epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), inducible nitric oxide synthase (iNOS), and latent membrane protein 1 (LMP-1) expression and with COX-2 promoter methylation status in primary nasopharyngeal cancer (NPC) tumors and to determine COX-2 promoter methylation status in NPC cell lines. Design: Retrospective study. Setting: Patients with NPC were referred to the Department of Otolaryngology-Head and Neck Surgery for treatment. Patients: Formalin-fixed, paraffin-embedded NPC specimens from 42 patients were obtained. Interventions: Immunohistochemical expression of COX-2, EGFR, VEGF, iNOS, and LMP-1 was performed in 42 NPC samples. COX-2 promoter methylation status was studied in 20 separate specimens and in 4 NPC cell lines. Main Outcome Measures: (1) COX-2, EGFR, VEGF, iNOS, and LMP-1 expression; and (2) COX-2 promoter methylation status. Results: COX-2 was overexpressed in 79% of NPC specimens and was associated with EGFR status (P=.03) but not with LMP-1 or iNOS. In primary NPC tissue, methylation of the COX-2 promoter was seen in 4 of 7 COX-2-negative and 1 of 13 COX-2-positive immunohistochemical cases. COX-2 promoter methylation was found in the CNE-1 cell line. Conclusions: Nasopharyngeal cancer may be a useful target for selective COX-2 inhibition. The absence of promoter methylation may be a necessary component of COX-2 overexpression, and promoter methylation may be one of the mechanisms that regulate COX-2 expression.

AB - Objectives: To examine the association between cyclooxygenase-2 (COX-2) expression with epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), inducible nitric oxide synthase (iNOS), and latent membrane protein 1 (LMP-1) expression and with COX-2 promoter methylation status in primary nasopharyngeal cancer (NPC) tumors and to determine COX-2 promoter methylation status in NPC cell lines. Design: Retrospective study. Setting: Patients with NPC were referred to the Department of Otolaryngology-Head and Neck Surgery for treatment. Patients: Formalin-fixed, paraffin-embedded NPC specimens from 42 patients were obtained. Interventions: Immunohistochemical expression of COX-2, EGFR, VEGF, iNOS, and LMP-1 was performed in 42 NPC samples. COX-2 promoter methylation status was studied in 20 separate specimens and in 4 NPC cell lines. Main Outcome Measures: (1) COX-2, EGFR, VEGF, iNOS, and LMP-1 expression; and (2) COX-2 promoter methylation status. Results: COX-2 was overexpressed in 79% of NPC specimens and was associated with EGFR status (P=.03) but not with LMP-1 or iNOS. In primary NPC tissue, methylation of the COX-2 promoter was seen in 4 of 7 COX-2-negative and 1 of 13 COX-2-positive immunohistochemical cases. COX-2 promoter methylation was found in the CNE-1 cell line. Conclusions: Nasopharyngeal cancer may be a useful target for selective COX-2 inhibition. The absence of promoter methylation may be a necessary component of COX-2 overexpression, and promoter methylation may be one of the mechanisms that regulate COX-2 expression.

UR - http://www.scopus.com/inward/record.url?scp=13444309421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13444309421&partnerID=8YFLogxK

U2 - 10.1001/archotol.131.2.147

DO - 10.1001/archotol.131.2.147

M3 - Article

C2 - 15723947

AN - SCOPUS:13444309421

VL - 131

SP - 147

EP - 152

JO - Archives of Otolaryngology

JF - Archives of Otolaryngology

SN - 2168-6181

IS - 2

ER -